Guardion Health Sciences (GHSI) Competitors

Genenta Science has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 20.2% of Guardion Health Sciences shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 1.3% of Guardion Health Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Guardion Health Sciences'average media sentiment score.

Guardion Health Sciences has a net margin of 22.79% compared to Genenta Science's net margin of 0.00%. Genenta Science's return on equity of 0.00% beat Guardion Health Sciences' return on equity.

Guardion Health Sciences has higher revenue and earnings than Genenta Science.

Guardion Health Sciences has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Guardion Health Sciences has a net margin of 22.79% compared to Natural Alternatives International's net margin of -9.06%. Natural Alternatives International's return on equity of -8.60% beat Guardion Health Sciences' return on equity.

20.2% of Guardion Health Sciences shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 1.3% of Guardion Health Sciences shares are owned by company insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Guardion Health Sciences has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.

In the previous week, Natural Alternatives International had 1 more articles in the media than Guardion Health Sciences. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Guardion Health Sciences. Guardion Health Sciences' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

In the previous week, Passage Bio had 1 more articles in the media than Guardion Health Sciences. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Guardion Health Sciences. Guardion Health Sciences' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Guardion Health Sciences has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.

Guardion Health Sciences has a net margin of 22.79% compared to Passage Bio's net margin of 0.00%. Guardion Health Sciences' return on equity of -73.69% beat Passage Bio's return on equity.

Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 221.60%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Guardion Health Sciences.

Guardion Health Sciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lexaria Bioscience has a consensus target price of $1.50, suggesting a potential upside of 122.42%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Guardion Health Sciences.

In the previous week, Guardion Health Sciences' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Guardion Health Sciences has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.

Guardion Health Sciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Guardion Health Sciences has a net margin of 22.79% compared to Lexaria Bioscience's net margin of -1,685.84%. Guardion Health Sciences' return on equity of -73.69% beat Lexaria Bioscience's return on equity.